Allogeneic hematopoietic cell transplantation for Hodgkin lymphoma: a concise review

References

• Schmitz N, Haverkamp H, Josting A, et al. Long term followup in advanced Hodgkins disease: updated results of the HD-R1 study comparing conventional chemotherapy to high-dose chemotherapy with autologous hematopoietic stem cell transplantation of the German Hodgkin Study Group (GHSG) and the Working Party of the European Group for Blood and Marrow Transplantation (EBMT). J Clin Oncol 2005; 23:562S
   Web of Science ®Google Scholar
• Moskowitz C H, Kewalramani T, Nimer S D, et al. Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin's disease. Br J Haematol 2004; 124: 645–652
   PubMed Web of Science ®Google Scholar
• Linch D C, Winfield D, Goldstone A H, et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet 1993; 341: 1051–1054
   PubMed Web of Science ®Google Scholar
• Anderlini P, Swanston N, Rashid A, et al. Evidence of a graft-versus-Hodgkin lymphoma effect in the setting of extensive bone marrow involvement. Biol Blood Marrow Transplant 2008; 14: 478–480
   PubMed Web of Science ®Google Scholar
• Thomson K J, Peggs K S, Smith P, et al. Superiority of reduced-intensity allogeneic transplantation over conventional treatment for relapse of Hodgkin's lymphoma following autologous stem cell transplantation. Bone Marrow Transplant 2008; 41: 765–770
   PubMed Web of Science ®Google Scholar
• Armand P, Kim H T, Ho V T, et al. Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome. Biol Blood Marrow Transplant 2008; 14: 418–425
   PubMed Web of Science ®Google Scholar
• Alvarez I, Sureda A, Caballero M D, et al. Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed hodgkin lymphoma: results of a spanish prospective cooperative protocol. Biol Blood Marrow Transplant 2006; 12: 172–183
   PubMed Web of Science ®Google Scholar
• Peniket A J, Ruiz de Elvira M C, Taghipour G, et al. An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation. Bone Marrow Transplant 2003; 31: 667–678
   PubMed Web of Science ®Google Scholar
• Gajewski J L, Phillips G L, Sobocinski K A, et al. Bone marrow transplants from HLA-identical siblings in advanced Hodgkin's disease. J Clin Oncol 1996; 14: 572–578
   PubMed Web of Science ®Google Scholar
• Anderson J E, Litzow M R, Appelbaum F R, et al. Allogeneic, syngeneic, and autologous marrow transplantation for Hodgkin's disease: the 21-year Seattle experience. J Clin Oncol 1993; 11: 2342–2350
   PubMed Web of Science ®Google Scholar
• Akpek G, Ambinder R F, Piantadosi S, et al. Long-term results of blood and marrow transplantation for Hodgkin's lymphoma. J Clin Oncol 2001; 19: 4314–4321
   PubMed Web of Science ®Google Scholar
• Armitage J O, Goldstone A H, Carella A M, . Role of bone marrow transplantation in Hodgkins disesae. Hodgkins Disease, P M Pauch, J O Armitage, V Diehl, R T Hoppe, L M Weiss, et al. Philadelphia, PA: Lippincott-Williams and Wilkins. 1999; 521–530
   Google Scholar
• Sureda A, Robinson S, Canals C, et al. Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2008; 26: 455–462
   PubMed Web of Science ®Google Scholar
• Anderlini P, Saliba R, Acholonu S, et al. Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience. Haematologica 2008; 93: 257–264
   PubMed Web of Science ®Google Scholar
• Peggs K S, Hunter A, Chopra R, et al. Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation. Lancet 2005; 365: 1934–1941
   PubMed Web of Science ®Google Scholar
• Burroughs L, O'Donnell P, Sandmaier B, et al. Comparison of allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning with HLA-matched related, unrelated and related haploidentical donors for relapsed or refractory Hodgkin lymphoma. Blood 2007; 110:58a
   Web of Science ®Google Scholar
• Carella A M, Cavaliere M, Lerma E, et al. Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma. J Clin Oncol 2000; 18: 3918–3924
   PubMed Web of Science ®Google Scholar
• Gallamini A, Hutchings M, Avigdor A, et al. Early interim PET scan in Hodgkin lymphoma: where do we stand?. Leuk Lymphoma 2008; 49: 659–662
   PubMed Web of Science ®Google Scholar
• Hutchings M, Loft A, Hansen M, et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 2006; 107: 52–59
   PubMed Web of Science ®Google Scholar
• Jabbour E, Hosing C, Ayers G, et al. Pretransplant positive positron emission tomography/gallium scans predict poor outcome in patients with recurrent/refractory Hodgkin lymphoma. Cancer 2007; 109: 2481–2489
   PubMed Web of Science ®Google Scholar